View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 8, 2020updated 12 Jul 2022 11:48am

Cynata Therapeutics gets approval for Covid-19 clinical trial

Australia-based Cynata Therapeutics has secured ethics committee approval to conduct a clinical trial of its Cymerus mesenchymal stem cells (MSCs) to treat adult Covid-19 patients admitted to intensive care.

Australia-based Cynata Therapeutics has secured ethics committee approval to conduct a clinical trial of its Cymerus mesenchymal stem cells (MSCs) to treat adult Covid-19 patients admitted to intensive care.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Called MEND, the open-label, randomised controlled trial will assess early efficacy of Cymerus MSCs. It builds on the company’s positive pre-clinical study results in ARDS, sepsis and cytokine release syndrome, which are known characteristics of severe Covid-19.

The study will be performed at sites in New South Wales in alliance with the Cerebral Palsy Alliance Research Institute and the Covid-19 Stem Cell Treatment (CSCT) Group investigators.

Cynata Therapeutics CEO and managing director Dr Ross Macdonald said: “Our substantial pre-clinical database in relevant disease models, together with the urgent need for more effective treatments for critically ill patients with Covid-19, allowed us to accelerate planning and rapidly achieve ethics committee approval.

“This trial forms part of a broader clinical development strategy for our Cymerus MSC product to be trialled in COVID-19 patients in other countries.

“Our decision to focus on this new clinical development area is a logical and prudent step based on the current global environment and Cynata’s solid pre-clinical foundations in respiratory and related diseases.”

The MEND trial will enrol a total of 24 adults admitted to intensive care due to Covid-19 and respiratory distress. Twelve patients will be given Cymerus MSC infusions plus standard of care, while the remaining will receive current standard of care.

Primary endpoints will be improvement in PaO2/FiO2 ratio by day 7, along with safety and tolerability up to day 28.

Currently, the company is exploring opportunities to expand the trial.

In preclinical studies, Cymerus MSCs have showed promise in various conditions caused by severe Covid-19, significantly in ARDS and other inflammatory conditions such as sepsis and cytokine release syndrome.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena